STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Ipamorelin

Also known as

IPA · Ipam · NNC 26-0161 · NNC26-0161 · NNC 260161 · Aib-His-D-2-Nal-D-Phe-Lys-NH2 · Ipamorelin acetate · Ipamorelin acetate salt · selective GHRP · third-generation GHRP (community label)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic Subcutaneous Growth hormone axis

Systemic ghrelin-receptor agonist discussed for GH pulses, sleep and recovery; not a targeted joint treatment.

What people say Ipamorelin is a ghrelin-receptor agonist discussed for sleep and recovery, alone or with CJC no-DAC / Mod GRF. Combination effects cannot be assigned to ipamorelin alone.It is not CJC, recombinant GH or a weekly depot. Doses people talk about
Common per-injection discussion100–300 mcg per dose

SC discussion includes nightly and repeated daily routines; 200–300 mcg recurs in solo accounts.

Selected solo-use accounts100 mcg 3–4 times/day; 250 mcg twice/day; 500 mcg before bed

Different posters, not one progression or comparative trial. Routes and products are unverified; the original post’s apparent “250 mg” typo is excluded.

Paired with CJC no-DAC100/100 or 200/200 mcg per injection

These name each peptide separately, not the total blend amount; nightly and repeated use appear in the notes.

The human IV study is separate from these community patterns; reported amounts are not safety-validated ranges.

Half-life & effect duration

Half-life in the body
  • IV infusion studyAbout 2 hours
  • Other reported IV estimatesAbout 2.4–3.1 hours at lower studied doses
Felt duration people report
  • Positive solo-use accountBetter sleep and energy after 5 days
  • Other solo-use accountNo sleep or recovery change after 2 weeks
Timing context & sources
How it may feel Solo accounts range from no sleep or recovery change after two weeks to deeper sleep and daytime energy within five days. Longer body-composition reports are mixed.
Cycles people discuss Discussions include 4–6-week probes, 8–12-week blocks, 5-on/2-off schedules and longer bedtime use. Timing Bedtime while fasted dominates discussion; morning and post-workout use appears in repeated-pulse accounts. Stacks CJC no-DAC / Mod GRF 1-29 + Ipamorelin (default): GHRH + GHRP dual-pulse stack; often co-injected same syringe or sold premixed; modal ratios ~100 mcg CJC + 100–300 mcg Ipam per pulse, 1–3×/day. Access talk 2026 shelves: leftover clinic/compounded IPA (often in a CJC blend), telehealth “peptide” pens, and RUO vials. A withdrawn nomination is not a bulks-list approval. Labs people mention IGF-1 is what people recheck to see if the axis moved. Solo IPA at community mcg is often described as a smaller IGF-1 nudge than IPA + GHRH or than somatropin IU charts. Watch for Injection site: Redness, itch, mild sting, or small swell — same-site reuse, cold solution, and technique are usual suspects.
Related
GHRP-2GHRP-6HexarelinMK-677Sermorelin

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 2 hours in a human intravenous-infusion study.

That is parent ipamorelin clearance—not the separate GH peak, and not a verified subcutaneous or blend half-life.

Do not transpose IV parent-peptide kinetics onto subcutaneous use, mixtures or the duration of hormonal changes.

Felt duration people report

One solo-use poster noticed better sleep and energy after five days; another noticed no sleep or recovery change after two weeks.

Those are course-onset and nonresponse reports, not an established per-dose window.

Reports neither establish efficacy nor how many people respond. No dosing conclusion is drawn from the source's unit ambiguity.

  • Ipamorelin only — contrasting first-person reports (opens in a new tab)Muted-Arrival-3308 two-week nonresponse opening; diggrecluse 500 mcg bedtime/five-day reply; separate 100 mcg 3–4/day and 250 mcg twice/day replies. Independent actual content inspection September 6. Opening 250 mg apparent typo excluded.Product identity and route are unverified. Original post contains an apparent dose-unit problem; that value and suggested regimens are not adopted.

What people say 13

  • Sleep: Bedtime empty-stomach dosing is heavily linked to deeper sleep, easier fall-asleep, and more vivid dreams in community logs — often the earliest ‘it did something’ signal. forum
  • Recovery: Multi-week reports of less next-day soreness and faster bounce-back between hard sessions — usually with training + often a GHRH partner; highly confounded. forum
  • Body composition: Lean-mass / recomp / mild fat-loss anecdotes over months; almost always confounded by diet, training, water shifts, and stacks — no large physique RCT. anecdote
  • Hunger control angle: Much less extreme appetite than GHRP-6; treated as a practical advantage on cuts or recomp where GHRP-6 wrecks adherence. A subset still notes mild appetite up. forum
  • Skin / fullness: Milder ‘GH look’ fullness or skin-quality notes; water retention can mimic the same look and must not be read as tissue alone. forum
  • Stack belief (dominant): Many physique wins are credited to Ipam + CJC (no DAC) dual pulse more than Ipamorelin alone — GHRH amplifies/prolongs the pulse narrative. forum
  • IGF-1 proxy: Some users track morning serum IGF-1 after multi-week runs as a crude ‘axis engaged’ check — not a validated outcome surrogate for muscle or fat loss, and single values are noisy. forum
  • Injury-season adjacency: Soft-tissue recovery feel is discussed when stacked with BPC-157/TB-500; Ipam is not a local healing peptide — any win is systemic GH/recovery lore plus confounders. forum
  • 2025–26 sleep-first still: X logs still say if sleep doesn’t move in 1–2 weeks, check empty-stomach bedtime timing before raising mcg. forum
  • Dose-dependent GH pulse: Clinical IV/PK work showed rising GH with dose; peak GH often ~30–45 min post-dose (some summaries ~40 min), then back toward baseline over a few hours — discrete pulse, not all-day elevation. trial
  • Vs older GHRPs (main selling point): Preferred when users want GH-axis work without GHRP-6-level hunger waves or the cortisol/prolactin spillover lore of GHRP-2/hexarelin; Raun animal data is the citation backbone for ‘selective’ marketing. animal
  • Animal growth / GH signals: Preclinical work showed strong GH release and growth-related signals without the older-GHRP ACTH/cortisol profile at GH-effective doses. animal
  • Clinic / wellness framing: Telehealth and compounding marketing push sleep, recovery, body comp, and ‘anti-aging’ — volume of marketing is not clinical proof for those endpoints. forum

Doses people talk about 25

  • 100/100 culture: Classic beginner chart: ~100 mcg ipamorelin with ~100 mcg CJC no-DAC per pin, often nightly or 1–2×/day. forum
  • Per-injection band (solo or stacked): ~100–300 mcg subcutaneous per dose is the constant beginner/intermediate range across forums, protocol sheets, and wellness writeups. forum
  • Common sweet spot: ~200–300 mcg per shot is repeatedly named as the modal single-agent research-chem / bodybuilding figure when run without a GHRH partner or as the Ipam half of a dual pulse. forum
  • Starter titration (solo): Many start ~100 mcg/pulse 1× daily (often bedtime) for 1–2 weeks, then titrate toward 200–300 mcg if sides stay mild and sleep/recovery feedback is the goal. forum
  • Frequency — sleep-first: 1× daily bedtime, empty stomach — most common ‘keep it simple’ template. forum
  • Frequency — multi-pulse: 2× daily (AM fasted + bedtime) or 3× daily (AM + post-workout + bedtime) for more aggressive GH-pulse exposure; each pulse still needs a fasted window in community rules. forum
  • Daily totals discussed: Roughly ~100–300 mcg/day (low/bedtime-only) up through ~600–900 mcg/day (e.g., 200–300 mcg × 2–3) in aggressive logs — higher daily totals track with more water/tingle talk, not proven better recomp. forum
  • Upper per-pulse talk: ~300–500 mcg per pulse appears in advanced logs; less consensus and more water/tingle/headache talk; some writeups claim diminishing GH returns past ~300 mcg/pulse (saturation lore — not a universal clinical Ipam ceiling). forum
  • Boom-dose anecdotes: Isolated old-forum claims of much higher single pulses (even mg-range pre-bed talk) exist; they are outliers, not a standard template, and increase side-effect discussion. anecdote
  • Saturation lore (stack math): Forum sheets often treat Mod GRF/CJC no-DAC as ~100 mcg receptor-saturation-ish for the GHRH side and pair it with Ipam 100–300 mcg rather than mega-dosing CJC alone; Ipam itself is still commonly run 200–300 mcg even when CJC stays at 100 mcg. forum
  • With CJC no-DAC / Mod GRF (paired per pulse): Stay in roughly Ipam 100–300 mcg + CJC/Mod GRF 100–200 mcg per injection — do not double Ipam just because it is stacked. Modal templates: 100 mcg CJC + 100 mcg Ipam; 100 mcg CJC + 200 mcg Ipam; 100–200 mcg CJC + 200–300 mcg Ipam. forum
  • Bedtime-only stack template: ~100 mcg CJC no-DAC + 200 mcg Ipam (or 100/100) pre-sleep, fasted — common ‘anti-aging / sleep’ clinic-forum hybrid. forum
  • Aggressive 2–3×/day stack template: 100–200 mcg CJC no-DAC + 200–300 mcg Ipam per pulse at AM fasted, optional post-workout, and bedtime. forum
  • Clinic unit-escalation marketing: Some wellness sites describe escalating multi-unit daily blend schedules (e.g., climbing total daily blend over weeks toward higher unit counts) — these are provider-specific marketing protocols, not a single standard research dose and not interchangeable with pure mcg-of-each charts. forum
  • 5-on / 2-off variant: Minority run weekday-only or 5 days on / 2 off at the same per-shot mcg to cut cost or chase receptor-rest folklore; superiority over daily is anecdotal. forum
  • Timing / food (critical community rule): Fasted window commonly ≥~2 hours after food (especially carbs/high glucose); ~30–90 min pre-sleep for night pulse; AM pulse often 30–60 min before first meal. Carbs near the dose are widely said to blunt the GH pulse. forum
  • Same-syringe debate: Dominant practice is draw both (or use premix) into one subq shot; a minority of writeups warn against mixing without compounder guidance — product inserts and stability data are inconsistent in the gray market. forum
  • 2025–26 extra camps: Bedtime-only ~200–300 mcg; 100 mcg feel-out; 2× (AM fasted + night); IPA-heavy 200–300 with CJC 100 when stacked. Solo 100 mcg is often called “noise” in advanced threads. forum
  • Split vs bedtime: Sleep people keep the night pin. Fat-loss / GLP-1 people add or switch to AM fasted so insulin is low. 3×/day still exists and still dies on meal timing. forum
  • Premixed blend vials: Often sold as 5 mg/5 mg or 10 mg/10 mg CJC+Ipam 1:1; common community draws target ~100–250 mcg of each per shot (e.g., total blend 200–500 mcg if 1:1) — always confirm label ratio (2:1 and other ratios exist). forum
  • Purity / fill flag: Labeled mcg may not match delivered peptide without third-party testing; research-chem and compounded products vary widely. forum
  • Reconstitution math (solo vials): 5 mg vs 10 mg labels plus 1–3 mL water only change *units on the syringe*. Copying someone else’s “6 units” without their water volume is the usual miss. This card still has no mix SOP. forum
  • Framing: Community, vendor, and clinic-marketing discussion ranges only — not advice, not prescriptions, not safety-validated athletic protocols. forum
  • Clinical mcg/kg (historical, not gym protocol): Gobburu-style human PK/PD used IV single-dose escalation on the order of ~0.003–0.1 mg/kg (3–100 mcg/kg); secondary writeups discuss SC50 for half-maximal GH stimulation around ~214 nmol/L — forums almost never use weight-based charts and use fixed mcg instead. trial
  • Phase II ileus dose (not gym protocol): ~0.03 mg/kg IV twice daily for up to ~7 days in postoperative bowel-surgery research — different route, goal, and duration than community subq use. trial

How it may feel 11

  • Minutes 0–15 post-shot: Usually little stim; peptide absorption beginning (community SC Tmax talk often ~15–30 min for peptide levels). forum
  • Nights 1–7: Sleep ease/depth is the most common early signal when bedtime + fasted is dialed; little daytime change for many. forum
  • Weeks 1–2: Sleep/recovery anecdotes peak first; scale weight or recomp change is rarely a clean week-one win. forum
  • Weeks 3–4: Community checkpoint for water/puffiness, hand tingling, recovery feel, product quality doubt, and whether a GHRH partner or fasted timing needs fixing before raising mcg. forum
  • Weeks 4–8: Window where multi-week recovery logs either stick or users call it placebo/underdosed/bad product; body-comp claims still diet-dependent. forum
  • Months 2–3: Gradual lean/recovery claims or plateau without diet/training/protocol changes; some add a second daily pulse here. forum
  • 2026 week-1–2: Deeper sleep before anything else remains the posted curve; no stim buzz. forum
  • Fed pin feel: 2025–26 logs that eat or drink calories inside the fasted window describe restlessness/heat instead of drowsiness. forum
  • GI / motility minority: Occasional 2026 posts blame nausea or bathroom urgency on pinning then lying down immediately — still anecdote, not a trial endpoint. anecdote
  • ~30–90 min post-shot: GH peak window from clinical timing; usually still no stim feel — minority note brief facial flush, warmth, light tingle, or mild drowsiness if dosed pre-bed. trial
  • Hours 2–4: GH effects fading toward baseline in PK/PD summaries; no residual ‘stim’ like amphetamines. trial

Around the dose 8

  • Clock: Night, often with a GHRH analog (CJC/Mod GRF or tesamorelin). Some split AM+PM. forum
  • Empty stomach: Same GH-axis lore — keep food away from the pin. forum
  • Training: Not a pump peptide. Night pin + next-day training is the usual picture. forum
  • Sleep: Hunger on ipamorelin is a real complaint; people who eat a huge meal after the pin are the ones arguing with the empty-stomach rule. forum
  • Empty-stomach night pin: Still the simple 2026 version — ~2+ hours after food, 15–30 min before sleep. Carbs near the dose are the blamed blunter. forum
  • Split vs bedtime: Night for sleep/recovery lore; morning fasted for a second pulse or when dinner was late. forum
  • After: Don’t eat; water is the usual exception. Hunger vs that rule is the GHS complaint (milder than GHRP-6, not always zero). forum
  • Not DAC logic: Short pulse. Weekly DAC CJC does not turn IPA into a weekly shot. forum

Cycles people discuss 11

  • Common physique/recovery block: 8–12 weeks on is the most repeated community template for Ipam ± CJC. forum
  • Short probe: 4–6 weeks to test sleep response, sides, injection tolerance, and whether the product feels active before committing longer. forum
  • Longer wellness template: ~12–16 weeks on, or clinic-style ~3 months on / ~1 month off, appears in marketing and multi-cycle year plans. forum
  • Time off after multi-month runs: Several weeks off (often ~4 weeks) — rationale is GHS-receptor sensitivity folklore, cost control, checking if sleep/recovery hold, and rechecking water/glucose feel. Not a proven mandatory PCT. forum
  • 5-on / 2-off microcycle: Minority schedule inside longer blocks; sometimes paired with training week structure; evidence of superiority is anecdotal. forum
  • Continuous low-freq use: Some longevity-oriented talk keeps bedtime-only long-term without formal offs; long-horizon safety in healthy self-experimenters is not established. forum
  • Bloodwork checkpoints (community practice): Baseline and mid/end-cycle talk often includes IGF-1, fasting glucose ± fasting insulin/HOMA-IR, and basic metabolic panel when stacks or aggressive multi-pulse runs are used — not a regulated standard. forum
  • Re-runs: Common around hard training blocks, contest-prep adjacency, injury seasons, or when sleep quality drops again after a break. forum
  • Stacked cycle length: When run with CJC no-DAC, cycle length usually follows the dual-peptide block (same 8–12+ weeks); when layered under TRT or GLP-1s, users often keep the GH-axis block as the limited piece. forum
  • Exit criteria discussed: Persistent carpal-tunnel-like tingling, unwanted water, headaches, glucose creep, or no subjective sleep/recovery benefit after timing/product fixes. forum
  • 2026 lab habit: IGF-1 + glucose at baseline and ~week 4–8; 8–12 weeks on / 3–4 off still the physique template in those sheets. forum

Timing 11

  • SC Tmax talk: Peptide plasma levels often described as peaking earlier (~15–30 min SC) than the GH peak itself. forum
  • IGF-1 lag: Acute GH pulse is immediate; circulating IGF-1 / recovery / composition claims are slower and accumulate over weeks of repeated dosing if they appear at all. forum
  • Food blunting: Carbs / high glucose near the dose are widely said to blunt the GH pulse — empty-stomach ritual is nearly universal in protocol sheets. forum
  • Vs MK-677: Short discrete injectable pulses vs long oral ghrelin-mimetic elevation with once-daily IGF-1 coverage; different hunger, water, and glucose discussion profiles. forum
  • Vs CJC with DAC: Ipam stays short-acting even if someone pairs it with long-acting GHRH — pulse logic for Ipam does not become weekly; many prefer no-DAC specifically so both halves stay pulsatile. forum
  • Vs CJC no-DAC alone: Dual pathway (GHRH + GHS) is the synergy story; Ipam without GHRH still pulses GH but is often described as ‘leaving half the stack on the table.’ forum
  • Desensitization lore: Partial GHS-receptor attenuation with chronic frequent use is discussed from older GHRP literature; drives off-blocks and 5-on/2-off folklore more than proven Ipam-specific long RCTs. forum
  • Human parent-peptide PK (IV): After a 15-minute IV infusion in healthy adult men, terminal half-life was about 2 hours, clearance 0.078 L/h/kg and steady-state distribution volume 0.22 L/kg. These measurements do not establish SC, nasal, oral or blend kinetics. trial
  • Separate GH response: In the IV study, the GH peak was about 0.67 hours (~40 minutes); older summaries describe ~30–45 minutes and a ~2–3-hour return toward baseline. These describe hormonal response, not parent-peptide half-life or proven SC timing. trial
  • Multi-daily discussion: The short-pulse framing is used to explain 1–3 separate daily uses instead of a weekly depot. That is community scheduling logic, not a regimen established by the IV parent-half-life study. forum
  • Rat nasal BA note: Historical PK work estimated ~20% intranasal bioavailability for ipamorelin in rat — explains minority nasal curiosity, not equivalence to subq mg-for-mg. animal

More on what it is 11

  • Why people use it: Framed as the ‘cleanest’ classic injectable GHRP — a short GH pulse with far less hunger, cortisol, and prolactin talk than GHRP-6, GHRP-2, or hexarelin. forum
  • Mechanism talk: Binds GHS-R1a on pituitary (and hypothalamus pathway talk) → acute GH release pulse; often co-dosed with a GHRH analog (CJC no-DAC / Mod GRF 1-29) so GHRH + GHS pathways fire together for a larger dual-pathway pulse. forum
  • Research lens: Forum ‘gains’ are almost always confounded by training, diet, sleep hygiene, and especially CJC/GHRH co-use; selectivity vs older GHRPs is real in animal head-to-heads but does not equal proven long-term athletic safety. forum
  • Clinic vs RUO: 2025–26 wellness shops still sell IPA in CJC blends or solo; displaced fills moved to research vials. Identity/fill risk is the practical talk. forum
  • Bro framing: “Clean” GHRP pulse for sleep/recovery — usually stacked with a GHRH analog, not run alone forever. forum
  • What it is: Synthetic pentapeptide growth hormone secretagogue (NNC 26-0161; Aib-His-D-2-Nal-D-Phe-Lys-NH2; ~711.85 Da; CAS often listed 170851-70-4) that acts as a selective agonist at the ghrelin receptor GHS-R1a. trial
  • Selectivity hook (preclinical cornerstone): Raun et al. 1998 (Eur J Endocrinol) — in swine/rodent work, GH release comparable to GHRP-6 potency/efficacy class without meaningful ACTH/cortisol (or prolactin) rise even at doses >> GH ED50 (often summarized as >200× GH ED50 still clean on ACTH/cortisol). animal
  • Human PK/PD anchor: Gobburu et al. 1999 (Pharm Res) modeled dose-dependent GH release in healthy volunteers; terminal plasma half-life ~2 h; peak GH on the order of ~30–45 min post-dose. trial
  • Clinical development honesty: Advanced into Phase II for postoperative ileus (NCT00672074; Beck et al. 2014) — IV 0.03 mg/kg BID up to ~7 days was well tolerated but did not show significant efficacy vs placebo on ileus endpoints; program discontinued for that indication. No large RCTs for body composition, sleep quality, or longevity. trial
  • Not: Not recombinant GH (somatropin), not a steroid/SARM, not MK-677 (oral continuous secretagogue), not FDA-approved for muscle, fat loss, sleep, or anti-aging. trial
  • 2026 access: October 2024 PCAC voted against 503A bulks-list inclusion after the nomination was withdrawn. Ipamorelin acetate remains 503B Category 2 on FDA’s Apr 2026 safety-risk page. July 2026 PCAC seven did not include it. trial

Stacks 12

  • CJC no-DAC / Mod GRF 1-29 + Ipamorelin (default): GHRH + GHRP dual-pulse stack; often co-injected same syringe or sold premixed; modal ratios ~100 mcg CJC + 100–300 mcg Ipam per pulse, 1–3×/day. forum
  • CJC with DAC + Ipamorelin: Still appears (weekly-ish DAC + daily Ipam pulses), but less favored when pure short pulses are the goal — DAC changes GH/IGF-1 time course toward more sustained elevation. forum
  • Sermorelin + Ipam: GHRH swap for users who prefer sermorelin (often clinic-prescribed) while keeping Ipam as the GHS trigger. forum
  • Tesamorelin + Ipam: Less common than CJC pairings; tesamorelin’s visceral-fat / HIV-lipodystrophy clinical history gets mixed into wellness protocols. forum
  • BPC-157 / TB-500 (‘heal + grow’): Injury-season or soft-tissue logs stack repair peptides with the GH-axis duo — highly confounded; not a mechanistic synergy claim with strong trials. forum
  • MK-677 combo or alternate: Oral continuous secretagogue compared or stacked; hunger, water, and glucose concerns dominate those threads; some alternate days rather than fully stack to limit GH-axis load. forum
  • TRT / men’s clinic context: Frequently layered on testosterone replacement in wellness-forum protocols; outcomes confounded by TRT itself. forum
  • GLP-1 / dual-agonist adjacency: Emerging recomp talk pairs retatrutide/tirzepatide-class fat loss with nightly CJC/Ipam for lean preservation — mg-vs-mcg confusion is common and dangerous if labels are misread. forum
  • Sleep hygiene stack: Dark room, fixed bedtime, magnesium, and late-carb control often co-credited with ‘Ipam sleep’ wins; DSIP sometimes named in the same sleep-peptide conversation. forum
  • Vs running alone: Many users never run Ipamorelin solo after seeing dual-pulse marketing; solo use still discussed for sleep-only goals or budget. forum
  • Vs exogenous HGH: Some compare cost/side profile of secretagogue stacks vs low-dose somatropin; secretagogues need a working pituitary and produce pulses, not flat exogenous GH. forum
  • Not typically stacked with high-dose hexarelin long-term: Rotation talk exists (desensitization folklore); continuous multi-GHRP stacking is less common than picking one GHS partner for CJC. forum

Access talk 5

  • 2026 shelves: leftover clinic/compounded IPA (often in a CJC blend), telehealth “peptide” pens, and RUO vials. A withdrawn nomination is not a bulks-list approval. forum
  • Not on the July 2026 PCAC seven. trial
  • 503A: Nomination withdrawn 2024; removed from 503A Category 2 ~27 Sept 2024; October 29, 2024 PCAC voted against adding ipamorelin (acetate and free base) to the 503A bulks list. trial
  • 503B: Ipamorelin acetate remains Category 2 (FDA page current 22 Apr 2026) for immunogenicity / peptide-characterization concerns and IV gastric-motility literature FDA cites for serious adverse events including death. trial
  • WADA: GH secretagogues stay prohibited in sport — not a “natural GH” loophole. trial

Labs people mention 4

  • IGF-1 is what people recheck to see if the axis moved. Solo IPA at community mcg is often described as a smaller IGF-1 nudge than IPA + GHRH or than somatropin IU charts. forum
  • Timing of the draw: morning; some skip the night pin. Random GH is too peaky to use as the scoreboard. forum
  • Glucose / insulin: class-level GH concern on longer or stacked runs; stronger when MK-677 or exogenous GH is in the same month. forum
  • If IGF-1 is flat: 2026 threads check product (fill/identity), empty-stomach timing, and whether they expected pulsatile GHS to lift trough IGF-1 like DAC or rGH. forum

Storage notes 3

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
  • Unit-math trap: Same mcg is different syringe marks at 1 mL vs 2 mL vs 3 mL water. Premixed CJC/IPA 1:1 vials hide IPA-heavy ratios. Still not a reconstitution chart. forum

Watch for 20

  • Injection site: Redness, itch, mild sting, or small swell — same-site reuse, cold solution, and technique are usual suspects. forum
  • Flush / warmth: Brief facial warmth or flush shortly after the shot in a minority of logs. anecdote
  • Water / puffiness: Mild bloat, ring tightness, or fuller face/hands/ankles; dose-, sodium-, and multi-pulse-sensitive; often eases or stabilizes after early weeks for some. forum
  • Headache / fatigue / dizziness: Minority reports; stacks, sleep disruption, dehydration, and calorie deficit often confound causality. forum
  • Joint stiffness / aches: Occasional fluid-related stiffness talk overlapping general GH-axis water effects. forum
  • Hunger (mild): Subset notes mild appetite up — still far less extreme than classic GHRP-6 hunger waves; not zero for everyone despite ‘no hunger’ marketing. forum
  • Vivid dreams / grogginess: Intense dreams or next-morning lethargy some users dislike with bedtime dosing; others call dreams a feature. anecdote
  • Glucose / insulin sensitivity: Theoretical and class-level concern that aggressive or long GH-axis stimulation can worsen insulin sensitivity; community monitoring talk includes fasting glucose, fasting insulin/HOMA-IR, and A1c on longer runs — stronger evidence base is general GH/secretagogue class than Ipam-specific long RCTs. forum
  • Prolactin/gyno lore vs GHRP-2: Community prefers Ipam over GHRP-2 partly to reduce prolactin-related anxiety; that preference is lore + older GHRP human spillover data, not proof Ipam never affects any off-target pathways at all doses. forum
  • Growth pathways / malignancy history: General GH/IGF-1 caution talk if active cancer history or high-risk context — class warning, not a compound-specific carcinogenicity table for community doses. forum
  • Nasal route cautions: Variable absorption, congestion technique issues, and non-equivalent dosing vs subq; rat ~20% BA is not a human subq conversion chart. forum
  • Not risk-free because ‘selective’: Selectivity vs older GHRPs does not equal proven long-term safety in healthy athletes or anti-aging self-experimenters; multi-month subq use at community doses lacks large controlled safety datasets. forum
  • Stack risk stacking: Water, glucose, and carpal-tunnel talk rise when Ipam is combined with DAC-CJC, MK-677, or exogenous GH — attribute sides to the whole axis load, not Ipam alone. forum
  • Water / carpal / glucose: Hand puff, median-nerve tingle, and fasting-glucose talk rise with multi-pulse or GH-axis stacks — community dose-cut signal. forum
  • Tingling / carpal-tunnel-like numbness: Hand/finger pins-and-needles framed as GH-related fluid pressure on the median nerve — more discussed on aggressive multi-pulse or stacked GH-axis runs; community responses include dose cut, off days, sodium control — not medical treatment. forum
  • Cortisol/prolactin (relative clean): Animal selectivity data (Raun 1998) is the main selling point; human side-by-side GHRP tables in secondary literature still treat Ipam as low spillover at discussion doses — not ‘zero systemic endocrine effect’ and not a free pass. animal
  • Pituitary dependence: Secretagogues require a responsive pituitary; not a substitute for rhGH in true GH deficiency without medical care. trial
  • Ileus program context: Phase II IV ileus trial (Beck 2014): 0.03 mg/kg BID up to 7 days well tolerated; treatment-related AE rates described as similar to placebo in that short surgical setting — not a long-term wellness safety proof and efficacy endpoint was not met. trial
  • Source / legal status: Gray-market purity and fill risk; research-only / compounded gray area depending on jurisdiction; no FDA-approved product for muscle, fat loss, sleep, or longevity. trial
  • 503B Category 2 leftover: FDA’s ipamorelin acetate 503B note still flags immunogenicity/characterization and cites IV ileus literature with serious events including death — not a subq lifestyle safety proof. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →